MEF2C regulates osteoclastogenesis and pathologic bone resorption via c-FOS

Abstract

Osteoporosis is a metabolic bone disease with dysregulated coupling between bone resorption and bone formation, which results in decreased bone mineral density. The MEF2C locus, which encodes the transcription factor MADS box transcription enhancer factor 2, polypeptide C (MEF2C), is strongly associated with adult osteoporosis and osteoporotic fractures. Although the role of MEF2C in bone and cartilage formation by osteoblasts, osteocytes, and chondrocytes has been studied, the role of MEF2C in osteoclasts, which mediate bone resorption, remains unclear. In this study, we identified MEF2C as a positive regulator of human and mouse osteoclast differentiation. While decreased MEF2C expression resulted in diminished osteoclastogenesis, ectopic expression of MEF2C enhanced osteoclast generation. Using transcriptomic and bioinformatic approaches, we found that MEF2C promotes the RANKL-mediated induction of the transcription factors c-FOS and NFATc1, which play a key role in osteoclastogenesis. Mechanistically, MEF2C binds to FOS regulatory regions to induce c-FOS expression, leading to the activation of NFATC1 and downstream osteoclastogenesis. Inducible deletion of Mef2c in mice resulted in increased bone mass under physiological conditions and protected mice from bone erosion by diminishing osteoclast formation in K/BxN serum induced arthritis, a murine model of inflammatory arthritis. Our findings reveal direct regulation of osteoclasts by MEF2C, thus adding osteoclasts as a cell type in which altered MEF2C expression or function can contribute to pathological bone remodeling.

References

[1] Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol., 2009, 5:667-676

[2] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423:337-342

[3] Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem., 2010, 285:25103-25108

[4] Zaidi M et al. Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Curr. Osteoporos. Rep., 2009, 7:118-126

[5] Ito H. Clinical considerations of regenerative medicine in osteoporosis. Curr. Osteoporos. Rep., 2014, 12:230-234

[6] Zheng HF et al. Meta-analysis of genome-wide studies identifies MEF2C SNPs associated with bone mineral density at forearm. J. Med. Genet., 2013, 50:473-478

[7] Rivadeneira F et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet., 2009, 41:1199-1206

[8] Velazquez-Cruz R et al. Analysis of association of MEF2C, SOST and JAG1 genes with bone mineral density in Mexican-Mestizo postmenopausal women. BMC Musculoskelet. Disord., 2014, 15

[9] Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science, 1997, 276:1404-1407

[10] Okamoto S, Krainc D, Sherman K, Lipton SA. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl Acad. Sci. USA, 2000, 97:7561-7566

[11] Arnold MA et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell, 2007, 12:377-389

[12] Wang W et al. MEF2C protects bone marrow B-lymphoid progenitors during stress haematopoiesis. Nat. Commun., 2016, 7

[13] Potthoff MJ, Olson EN. MEF2: a central regulator of diverse developmental programs. Development, 2007, 134:4131-4140

[14] Lin Q et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development, 1998, 125:4565-4574

[15] Collette NM et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc. Natl Acad. Sci. USA, 2012, 109:14092-14097

[16] Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J. Bone Min. Res., 2012, 27:360-373

[17] Kawane T et al. Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression. J. Bone Min. Res, 2014, 29:1960-1969

[18] Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab., 2012, 23:582-590

[19] Takayanagi H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell, 2002, 3:889-901

[20] Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J. Bone Metab., 2014, 21:233-241

[21] Takayanagi H et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 2002, 416:744-749

[22] Grigoriadis AE et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science, 1994, 266:443-448

[23] Sato K et al. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat. Med., 2006, 12:1410-1416

[24] Sorensen MG et al. Characterization of osteoclasts derived from CD14⁺ monocytes isolated from peripheral blood. J. Bone Min. Metab., 2007, 25:36-45

[25] Murata K et al. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity, 2017, 47:66-79 e65

[26] Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science, 1995, 269:1427-1429

[27] Charles JF et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Investig., 2012, 122:4592-4605

[28] Bae S et al. MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRalpha. J. Clin. Investig., 2017, 127:2555-2568

[29] Park-Min KH. Mechanisms involved in normal and pathological osteoclastogenesis. Cell Mol. Life Sci., 2018, 75:2519-2528

[30] Johnson ME et al. A ChIP-seq-defined genome-wide map of MEF2C binding reveals inflammatory pathways associated with its role in bone density determination. Calcif. Tissue Int., 2014, 94:396-402

[31] Kang K et al. IFN-gamma selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation. Nat. Commun., 2019, 10

[32] Fang C et al. Cutting edge: EZH2 promotes osteoclastogenesis by epigenetic silencing of the negative regulator IRF8. J. Immunol., 2016, 196:4452-4456

[33] Kang K et al. Interferon-gamma represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity, 2017, 47:235-250 e234

[34] Danks L, Sabokbar A, Gundle R, Athanasou NA. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis., 2002, 61:916-921

[35] Fujii T et al. Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion. RMD Open, 2017, 3

[36] Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10:537-543

[37] Leifer D et al. MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. Proc. Natl Acad. Sci. USA, 1993, 90:1546-1550

[38] Martin JF, Schwarz JJ, Olson EN. Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF-2 family of transcription factors. Proc. Natl Acad. Sci. USA, 1993, 90:5282-5286

[39] Estrada K et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet., 2012, 44:491-501

[40] Duncan EL et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet., 2011, 7

[41] Zhang L et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum. Mol. Genet., 2014, 23:1923-1933

[42] Miska EA et al. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J., 1999, 18:5099-5107

[43] Wein MN et al. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J. Bone Min. Res., 2015, 30:400-411

[44] Nakatani T, Partridge NC. MEF2C interacts with c-FOS in PTH-stimulated Mmp13 gene expression in osteoblastic cells. Endocrinology, 2017, 158:3778-3791

[45] Feng H et al. Myocyte enhancer factor 2 and microphthalmia-associated transcription factor cooperate with NFATc1 to transactivate the V-ATPase d2 promoter during RANKL-induced osteoclastogenesis. J. Biol. Chem., 2009, 284:14667-14676

[46] Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N. Engl. J. Med., 1986, 314:1676-1686

[47] Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J. Bone Min. Res., 2011, 26:441-451

[48] Park-Min KH et al. Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat. Commun., 2014, 5

[49] Park-Min KH et al. Negative regulation of osteoclast precursor differentiation by CD11b and beta2 integrin-B-cell lymphoma 6 signaling. J. Bone Min. Res., 2013, 28:135-149

[50] Parfitt AM et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Min. Res., 1987, 2:595-610

[51] Korganow AS et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity, 1999, 10:451-461

[52] Kawamoto T, Kawamoto K. Preparation of thin frozen sections from nonfixed and undecalcified hard tissues using Kawamot’s film method (2012). Methods Mol. Biol., 2014, 1130:149-164

[53] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001, 25:402-408

[54] Kusnadi A et al. The Cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair. Immunity, 2019, 51:241-257 e9

[55] Subramanian A et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 2005, 102:15545-15550

Funding

U.S. Department of Health & Human Services | National Institutes of Health (NIH)(5R01 AR069562)

U.S. Department of Health & Human Services | National Institutes of Health (NIH)